Seattle Genetics, Inc. (SGEN – Analyst Report) announced that it has actually initiated a phase III trial, CASCADE, about vadastuximab talirine (SGN-CD33A).
The randomized, double-blind, placebo-controlled trial will certainly evaluate if vadastuximab talirine, in combination along with Vidaza or Dacogen, can easily expand total survival compared to Vidaza or Dacogen alone in older patients along with newly diagnosed acute myeloid leukemia (AML).
We note that Vidaza and Dacogen are hypomethylating agents (HMAs) that are usually maximized for the procedure of older AML patients.
According to the American Cancer Society, AML will certainly impact 20,000 people in the U.S. in 2016, and lead to 10,500 deaths. Hence, there is considerable demand for procedures in this area.
The trial will certainly enroll 500 patients globally that will certainly be randomized about a 1:1 ratio to be treated along with an HMA plus 33A or an HMA plus placebo.
Interim outcomes from the ongoing phase I study, analyzing 33A in combination along with HMAs in frontline AML and as monotherapy in primarily relapsed AML, were presented in 2015. Data from the phase I 33A combination trial showed that 15 from 23 (65%) evaluable patients obtained finish remission and finish remission along with incomplete hematologic recovery (CR/Cri). Updated data from the ongoing phase I study about 33A in combination along with HMAs will certainly be presented in an oral presentation at the 2016 European Hematology Association Congress scheduled following month.
Meanwhile, Seattle Genetics is analyzing 33A across multiple lines of treatment in patients along with AML and myelodysplastic syndromes (MDS) in different trials.
We note that Adcetris is the just marketed product in Seattle Genetics’ portfolio, which has actually earned the business highly dependent about the drug for growth. As a result, the progress of pipeline candidates is crucial for the business to minimize its dependence about Adectris. Successful progress and commercialization of vadastuximab talirine will certainly raise Seattle Genetics’ best line significantly.
Seattle Genetics carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the medical sector contain Abbott Laboratories (ABT – Analyst Report) , Johnson & Johnson (JNJ – Analyst Report) and Sanofi (SNY – Analyst Report) . every one of 3 stocks carry a Zacks Rank #2 (Buy).
Want the most recent advice from Zacks Investment Research? Today, you can easily download 7 Finest Stocks for the following 30 Days.Click to get hold of this free report >>
